{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:19:17Z","timestamp":1793117957079,"version":"4.5.0"},"reference-count":363,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,17]],"date-time":"2022-01-17T00:00:00Z","timestamp":1642377600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.phrs.2022.106078","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T11:56:48Z","timestamp":1641815808000},"page":"106078","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"special_numbering":"C","title":["Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective"],"prefix":"10.1016","volume":"176","author":[{"given":"Andrea","family":"de Bartolomeis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarita","family":"Barone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Begni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco Andrea","family":"Riva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"419","key":"10.1016\/j.phrs.2022.106078_bib1","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1192\/bjp.100.419.543","article-title":"Preliminary observations on the psychiatric uses of chlorpromazine (largactil)","volume":"100","author":"Anton-Stephens","year":"1954","journal-title":"J. Ment. Sci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/0957154X07070335","article-title":"The history of clozapine and its emergence in the US market: a review and analysis","volume":"18","author":"Crilly","year":"2007","journal-title":"Hist. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib3","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","article-title":"Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride","volume":"27","author":"Yokoi","year":"2002","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/157015909790031229","article-title":"Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part I","volume":"7","author":"Miller","year":"2009","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib5","series-title":"Atypical Antipsychotics","first-page":"191","article-title":"Multireceptor atypical antipsychotic drugs","author":"Meltzer","year":"2000"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib6","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1176\/ajp.155.4.505","article-title":"Binding of antipsychotic drugs to cortical 5-HT2A receptors: a PET study of chlorpromazine, clozapine, and amisulpride in schizophrenic patients","volume":"155","author":"Trichard","year":"1998","journal-title":"Am. J. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib7","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1176\/appi.ajp.159.2.180","article-title":"Amisulpride, an unusual \u201catypical\u201d antipsychotic: a meta-analysis of randomized controlled trials","volume":"159","author":"Leucht","year":"2002","journal-title":"Am. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib8","first-page":"268","article-title":"Atypicality of atypical antipsychotics","volume":"7","author":"Farah","year":"2005","journal-title":"Prim. Care Companion J. Clin. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.schres.2017.07.041","article-title":"A computational network analysis based on targets of antipsychotic agents","volume":"193","author":"Gao","year":"2018","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib10","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1001\/archpsyc.60.10.974","article-title":"Mechanism of new antipsychotic medications: occupancy is not just antagonism","volume":"60","author":"Grunder","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib11","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.phrs.2018.12.001","article-title":"A fresh look at cortical dopamine D2 receptor expressing neurons","volume":"139","author":"Quintana","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.pbb.2011.08.023","article-title":"Parametric and pharmacological modulations of latent inhibition in mouse inbred strains","volume":"100","author":"Lipina","year":"2011","journal-title":"Pharmacol., Biochem., Behav."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib13","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1159\/000337132","article-title":"Neurobiological correlates of delusion: beyond the salience attribution hypothesis","volume":"66","author":"Pankow","year":"2012","journal-title":"Neuropsychobiology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1001\/archpsyc.1992.01820070032005","article-title":"Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects","volume":"49","author":"Farde","year":"1992","journal-title":"Arch. Gen. Psychiatry"},{"issue":"Suppl","key":"10.1016\/j.phrs.2022.106078_bib15","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/BF00442555","article-title":"D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics","volume":"99","author":"Farde","year":"1989","journal-title":"Psychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib16","article-title":"Stahl\u2019s Essential Psychopharmacology: neuroscientific basis and practical applications","volume":"19","author":"Elbe","year":"2010","journal-title":"J. Can. Acad. Child Adolesc. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib17","doi-asserted-by":"crossref","first-page":"488","DOI":"10.2174\/138161210790361461","article-title":"Third generation antipsychotic drugs: partial agonism or receptor functional selectivity?","volume":"16","author":"Mailman","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2165\/00023210-200418040-00005","article-title":"Dopamine partial agonists: a new class of antipsychotic","volume":"18","author":"Lieberman","year":"2004","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib19","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/2045125316672136","article-title":"Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole","volume":"7","author":"Frankel","year":"2017","journal-title":"Ther. Adv. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1092852915000954","article-title":"Mechanism of action of brexpiprazole: comparison with aripiprazole","volume":"21","author":"Stahl","year":"2016","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib21","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/s00213-014-3704-1","article-title":"Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission","volume":"232","author":"Snyder","year":"2015","journal-title":"Psychopharmacology"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0026-895X(25)10283-6","article-title":"Dopamine autoreceptor regulation of the kinetic state of striatal tyrosine hydroxylase","volume":"29","author":"Strait","year":"1986","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib23","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1471-4159.1986.tb12919.x","article-title":"Presynaptic dopamine autoreceptors control tyrosine hydroxylase activation in depolarized striatal dopaminergic terminals","volume":"46","author":"el Mestikawy","year":"1986","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib24","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.phrs.2013.01.002","article-title":"Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors","volume":"70","author":"McCormick","year":"2013","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0893-133X(98)00066-9","article-title":"Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons","volume":"20","author":"Gurevich","year":"1999","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib26","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/syn.21631","article-title":"Brain uptake and distribution of the dopamine D3 \/D2 receptor partial agonist [11 C]cariprazine: an in vivo positron emission tomography study in nonhuman primates","volume":"67","author":"T\u00f3th","year":"2013","journal-title":"Synapse"},{"key":"10.1016\/j.phrs.2022.106078_bib27","first-page":"297","article-title":"Dopamine D3 receptors inhibit hippocampal gamma oscillations by disturbing CA3 pyramidal cell firing synchrony","volume":"6","author":"Lemercier","year":"2015","journal-title":"Front. Pharmacol."},{"issue":"19\u201320","key":"10.1016\/j.phrs.2022.106078_bib28","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1007\/s00213-016-4382-y","article-title":"Preferential binding to dopamine D3 over D2 receptors by cariprazine in patients with schizophrenia using PET with the D3\/D2 receptor ligand [(11)C]-(+)-PHNO","volume":"233","author":"Girgis","year":"2016","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib29","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s00213-011-2343-z","article-title":"Occupancy of dopamine D\u2082 and D\u2083 and serotonin 5-HT\u2081A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography","volume":"218","author":"Seneca","year":"2011","journal-title":"Psychopharmacology"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib30","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s00210-012-0797-0","article-title":"Direct and indirect interactions of the dopamine D\u2083 receptor with glutamate pathways: implications for the treatment of schizophrenia","volume":"386","author":"Sokoloff","year":"2013","journal-title":"Naunyn-Schmiede\u2019s Arch. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib31","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1017\/S1092852916000894","article-title":"Long-term effects of aripiprazole exposure on monoaminergic and glutamatergic receptor subtypes: comparison with cariprazine","volume":"22","author":"Choi","year":"2017","journal-title":"CNS Spectr."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib32","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1177\/0269881111409265","article-title":"Increased prefrontal cortical D\u2081 receptors in drug naive patients with schizophrenia: a PET study with [11C]NNC112","volume":"26","author":"Abi-Dargham","year":"2012","journal-title":"J. Psychopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib33","first-page":"166","article-title":"Probing cortical dopamine function in schizophrenia: what can D1 receptors tell us?","volume":"2","author":"Abi-Dargham","year":"2003","journal-title":"World Psychiatry.: Off. J. World Psychiatr. Assoc. (WPA)"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/BF02246068","article-title":"Lack of apparent antipsychotic effect of the D1-dopamine receptor antagonist SCH39166 in acutely ill schizophrenic patients","volume":"121","author":"Karlsson","year":"1995","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0022-3565(24)36983-6","article-title":"Dose-dependent effects of the dopamine D1 receptor agonists A77636 or SKF81297 on spatial working memory in aged monkeys","volume":"283","author":"Cai","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib36","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1600-0773.1999.tb01482.x","article-title":"Clozapine: dopamine D1 receptor agonism in the prefrontal cortex as the code to decipher a Rosetta stone of antipsychotic drugs","volume":"84","author":"Ahlenius","year":"1999","journal-title":"Pharmacol. Toxicol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib37","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1124\/mol.56.5.989","article-title":"Inverse agonist properties of dopaminergic antagonists at the D(1A) dopamine receptor: uncoupling of the D(1A) dopamine receptor from G(s) protein","volume":"56","author":"Cai","year":"1999","journal-title":"Mol. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib38","doi-asserted-by":"crossref","DOI":"10.1085\/jgp.201912492","article-title":"Constitutive activity of dopamine receptor type 1 (D1R) increases CaV2.2 currents in PFC neurons","volume":"152","author":"McCarthy","year":"2020","journal-title":"J. Gen. Physiol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib39","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41386-018-0251-1","article-title":"Dopamine D(2) receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia","volume":"44","author":"Vanover","year":"2019","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2019.134343","article-title":"Alteration in the phosphorylation status of NMDA receptor GluN2B subunit by activation of both NMDA receptor and L-type voltage gated calcium channel","volume":"709","author":"Kumar","year":"2019","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1472-8206.2000.tb00437.x","article-title":"Dopamine D4 receptors and development of newer antipsychotic drugs","volume":"14","author":"Kulkarni","year":"2000","journal-title":"Fundam. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib42","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/0014-2999(93)90488-4","article-title":"Dopamine D4 versus D2 receptor selectivity of dopamine receptor antagonists: possible therapeutic implications","volume":"236","author":"Lahti","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112925","article-title":"Lack of dopamine D4 receptor participation in mouse hyperdopaminergic locomotor response","volume":"396","author":"Liao","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0040906","article-title":"Dopamine D4 receptor activation increases hippocampal gamma oscillations by enhancing synchronization of fast-spiking interneurons","volume":"7","author":"Andersson","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.2174\/1389450111314040012","article-title":"Targeted D4 dopamine receptors: implications for drug discovery and therapeutic development","volume":"14","author":"Pt\u00e1\u010dek","year":"2013","journal-title":"Curr. Drug Targets"},{"issue":"25","key":"10.1016\/j.phrs.2022.106078_bib46","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","article-title":"The role of 5-HT2A receptors in antipsychotic activity","volume":"56","author":"Schmidt","year":"1995","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib47","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","article-title":"Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values","volume":"251","author":"Meltzer","year":"1989","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106078_bib48","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/BF02245606","article-title":"Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding","volume":"124","author":"Schotte","year":"1996","journal-title":"Psychopharmacology"},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib49","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/WNR.0b013e328352de40","article-title":"5-HT1A and 5-HT7 receptors contribute to lurasidone-induced dopamine efflux","volume":"23","author":"Huang","year":"2012","journal-title":"Neuroreport"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib50","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1124\/jpet.110.167346","article-title":"Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity","volume":"334","author":"Ishibashi","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib51","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.2174\/138945009789735129","article-title":"Therapeutic potential of 5-HT7 receptors in mood disorders","volume":"10","author":"Mnie-Filali","year":"2009","journal-title":"Curr. Drug Targets"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib52","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2174\/138161210790361470","article-title":"Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism","volume":"16","author":"McCreary","year":"2010","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib53","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-011-2561-4","article-title":"The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats","volume":"221","author":"Horiguchi","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib54","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.bbr.2013.04.008","article-title":"Amisulpride promotes cognitive flexibility in rats: the role of 5-HT7 receptors","volume":"248","author":"Nikiforuk","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib55","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/ijms22031351","article-title":"Effects of subchronic administrations of vortioxetine, lurasidone, and escitalopram on thalamocortical glutamatergic transmission associated with serotonin 5-HT7 receptor","volume":"22","author":"Okada","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib56","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1016\/j.euroneuro.2015.07.007","article-title":"Lurasidone and fluoxetine reduce novelty-induced hypophagia and NMDA receptor subunit and PSD-95 expression in mouse brain","volume":"25","author":"Stan","year":"2015","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib57","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cpt.2282","article-title":"Discovery of nonracemic amisulpride to maximize benefit\/risk of 5-HT7 and D2 receptor antagonism for the treatment of mood disorders","volume":"110","author":"Hopkins","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2022.106078_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2020.112946","article-title":"\u03b17 nicotinic receptor agonist and positive allosteric modulators differently improved schizophrenia-like cognitive deficits in male rats","volume":"397","author":"Unal","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib59","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.neuropharm.2006.08.023","article-title":"Antipsychotic clozapine inhibits the function of alpha7-nicotinic acetylcholine receptors","volume":"52","author":"Singhal","year":"2007","journal-title":"Neuropharmacology"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2022.106078_bib60","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.schres.2013.06.007","article-title":"Intermittent versus continuous central administration of clozapine in DBA\/2 mice, improvement in sensory inhibition deficits","volume":"149","author":"Stevens","year":"2013","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib61","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neuropharm.2012.06.040","article-title":"Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study","volume":"64","author":"Winterer","year":"2013","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib62","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s00213-002-1285-x","article-title":"Clozapine improves deficient inhibitory auditory processing in DBA\/2 mice, via a nicotinic cholinergic mechanism","volume":"165","author":"Simosky","year":"2003","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.neuroscience.2013.08.008","article-title":"Dopamine D\u2082 and acetylcholine \u03b17 nicotinic receptors have subcellular distributions favoring mediation of convergent signaling in the mouse ventral tegmental area","volume":"252","author":"Garz\u00f3n","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2022.106078_bib64","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroscience.2019.07.003","article-title":"In vivo pharmacological comparison of TAK-071, a positive allosteric modulator of muscarinic M(1) receptor, and xanomeline, an agonist of muscarinic M(1)\/M(4) receptor, in rodents","volume":"414","author":"Mandai","year":"2019","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib65","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/0269881120946288","article-title":"Contributions of cholinergic receptor muscarinic 1 and CYP1A2 gene variants on the effects of plasma ratio of clozapine\/N-desmethylclozapine on working memory in schizophrenia","volume":"35","author":"Islam","year":"2021","journal-title":"J. Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105641","article-title":"Functionally selective and biased agonists of muscarinic receptors","volume":"169","author":"Rand\u00e1kov\u00e1","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib67","doi-asserted-by":"crossref","first-page":"2897","DOI":"10.1007\/s00213-018-4980-y","article-title":"Mutual activation of glutamatergic mGlu(4) and muscarinic M(4) receptors reverses schizophrenia-related changes in rodents","volume":"235","author":"Cie\u015blik","year":"2018","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib68","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1124\/jpet.111.188797","article-title":"Xanomeline modulation of the blood oxygenation level-dependent signal in awake rats: development of pharmacological magnetic resonance imaging as a translatable pharmacodynamic biomarker for central activity and dose selection","volume":"341","author":"Baker","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.phrs.2022.106078_bib69","unstructured":"A Study to Assess Safety and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-1), Karuna Therapeutics, 2020."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib70","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic Cholinergic receptor agonist and peripheral antagonist for schizophrenia","volume":"384","author":"Brannan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2022.106078_bib71","unstructured":"A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia, Cerevel Therapeutics, LLC, 2021."},{"issue":"19","key":"10.1016\/j.phrs.2022.106078_bib72","doi-asserted-by":"crossref","first-page":"3497","DOI":"10.1007\/s00213-015-4002-2","article-title":"Histamine H1 receptor occupancy by the new-generation antipsychotics olanzapine and quetiapine: a positron emission tomography study in healthy volunteers","volume":"232","author":"Sato","year":"2015","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib73","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/appy.12186","article-title":"Antipsychotics as antidepressants","volume":"8","author":"Roberts","year":"2016","journal-title":"Asia-Pac. Psychiatry.: Off. J. Pac. Rim Coll. Psychiatr."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib74","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40263-013-0062-1","article-title":"The role of hypothalamic H1 receptor antagonism in antipsychotic-induced weight gain","volume":"27","author":"He","year":"2013","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib75","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/JCP.0b013e318283963b","article-title":"Histamine H4 receptor polymorphism: a potential predictor of risperidone efficacy","volume":"33","author":"Wei","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib76","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib77","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib78","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0920-9964(98)00146-7","article-title":"Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro","volume":"37","author":"Bymaster","year":"1999","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib79","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0026-895X(25)08945-X","article-title":"In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone","volume":"41","author":"Leysen","year":"1992","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib80","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fpsyt.2017.00144","article-title":"Therapeutic potential of selectively targeting the \u03b1(2C)-adrenoceptor in cognition, depression, and schizophrenia-new developments and future perspective","volume":"8","author":"Uys","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib81","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0306-4522(98)00306-6","article-title":"Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns","volume":"88","author":"Bj\u00f6rklund","year":"1999","journal-title":"Neuroscience"},{"issue":"1\u20133","key":"10.1016\/j.phrs.2022.106078_bib82","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0014-2999(03)01308-6","article-title":"alpha2C-Adrenoceptor blockade by clozapine and other antipsychotic drugs","volume":"462","author":"Kalkman","year":"2003","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/pcn.12823","article-title":"Glutamate hypothesis in schizophrenia","volume":"73","author":"Uno","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib84","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","article-title":"Recent advances in the phencyclidine model of schizophrenia","volume":"148","author":"Javitt","year":"1991","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib85","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/schbul\/sbs076","article-title":"NMDA receptor and schizophrenia: a brief history","volume":"38","author":"Coyle","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib86","doi-asserted-by":"crossref","first-page":"241","DOI":"10.3109\/10673229609017192","article-title":"The glutamatergic dysfunction hypothesis for schizophrenia","volume":"3","author":"Coyle","year":"1996","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib87","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jpsychires.2020.04.005","article-title":"The positive allosteric modulator of the mGlu2 receptor JNJ-46356479 partially improves neuropathological deficits and schizophrenia-like behaviors in a postnatal ketamine mice model","volume":"126","author":"Mart\u00ednez-Pinte\u00f1o","year":"2020","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib88","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.neuropharm.2018.07.013","article-title":"Investigating the role of mGluR2 versus mGluR3 in antipsychotic-like effects, sleep-wake architecture and network oscillatory activity using novel Han Wistar rats lacking mGluR2 expression","volume":"140","author":"Wood","year":"2018","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/npp.2011.181","article-title":"From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment","volume":"37","author":"Moghaddam","year":"2012","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib90","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fpsyt.2019.00049","article-title":"Targeting mGlu receptors for optimization of antipsychotic activity and disease-modifying effect in schizophrenia","volume":"10","author":"Nicoletti","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib91","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1358\/dot.2018.54.12.2899443","article-title":"Lumateperone: a new treatment approach for neuropsychiatric disorders","volume":"54","author":"Kumar","year":"2018","journal-title":"Drugs Today"},{"key":"10.1016\/j.phrs.2022.106078_bib92","doi-asserted-by":"crossref","first-page":"369","DOI":"10.3389\/fpsyt.2020.00369","article-title":"Glycine signaling in the framework of dopamine-glutamate interaction and postsynaptic density. Implications for treatment-resistant schizophrenia","volume":"11","author":"de Bartolomeis","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib93","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in Negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biol. Psychiatry"},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib94","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.euroneuro.2014.03.007","article-title":"A phase II\/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study","volume":"24","author":"Bugarski-Kirola","year":"2014","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib95","unstructured":"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Negative Symptoms of Schizophrenia, Avanir Pharmaceuticals, 2019."},{"key":"10.1016\/j.phrs.2022.106078_bib96","unstructured":"Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Residual Schizophrenia, Avanir Pharmaceuticals, 2020."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib97","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.4693","article-title":"Association of Ketamine with psychiatric symptoms and implications for its therapeutic use and for understanding schizophrenia: a systematic review and meta-analysis","volume":"3","author":"Beck","year":"2020","journal-title":"JAMA Netw. Open"},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib98","article-title":"A review of samidorphan: a novel opioid antagonist","volume":"11","author":"Chaudhary","year":"2019","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib99","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of olanzapine combined with samidorphan on weight gain in schizophrenia: A 24-week phase 3 study","volume":"177","author":"Correll","year":"2020","journal-title":"Am. J. Psychiatry"},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib100","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1038\/s41386-020-0730-z","article-title":"Opioid antagonists are associated with a reduction in the symptoms of schizophrenia: a meta-analysis of controlled trials","volume":"45","author":"Clark","year":"2020","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib101","doi-asserted-by":"crossref","first-page":"920","DOI":"10.2174\/138161212799436584","article-title":"The ligand binding region of the sigma-1 receptor: studies utilizing photoaffinity probes, sphingosine and N-alkylamines","volume":"18","author":"Ruoho","year":"2012","journal-title":"Curr. Pharm. Des."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib102","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0014-2999(99)00852-3","article-title":"sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures","volume":"388","author":"Shimazu","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"Suppl 3","key":"10.1016\/j.phrs.2022.106078_bib103","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1055\/s-2004-832676","article-title":"Behavioral pharmacology of sigma-ligands","volume":"37","author":"Skuza","year":"2004","journal-title":"Pharmacopsychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib104","doi-asserted-by":"crossref","first-page":"344","DOI":"10.2174\/157015908787386113","article-title":"Pharmacology and therapeutic potential of sigma(1) receptor ligands","volume":"6","author":"Cobos","year":"2008","journal-title":"Curr. Neuropharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib105","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.euroneuro.2011.08.002","article-title":"Evaluation of sigma (\u03c3) receptors in the antidepressant-like effects of ketamine in vitro and in vivo","volume":"22","author":"Robson","year":"2012","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib106","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.expneurol.2007.06.013","article-title":"A comparison of the binding profiles of dextromethorphan, memantine, fluoxetine and amitriptyline: treatment of involuntary emotional expression disorder","volume":"207","author":"Werling","year":"2007","journal-title":"Exp. Neurol."},{"issue":"20","key":"10.1016\/j.phrs.2022.106078_bib107","doi-asserted-by":"crossref","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib108","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ygeno.2004.11.010","article-title":"Trace amine-associated receptors form structurally and functionally distinct subfamilies of novel G protein-coupled receptors","volume":"85","author":"Lindemann","year":"2005","journal-title":"Genomics"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib109","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity","volume":"324","author":"Lindemann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib110","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1038\/npp.2015.65","article-title":"TAAR1 modulates cortical glutamate NMDA receptor function","volume":"40","author":"Espinoza","year":"2015","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib111","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1111\/j.1601-183X.2006.00292.x","article-title":"The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia","volume":"6","author":"Wolinsky","year":"2007","journal-title":"Genes, Brain, Behav."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib112","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight","volume":"18","author":"Revel","year":"2013","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib113","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1038\/npp.2016.216","article-title":"Trace Amine-associated Receptor 1 Regulates Wakefulness and EEG spectral composition","volume":"42","author":"Schwartz","year":"2017","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib114","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10571-019-00757-6","article-title":"The action of TAAR1 agonist RO5263397 on executive functions in rats","volume":"40","author":"Dorotenko","year":"2020","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.phrs.2022.106078_bib115","doi-asserted-by":"crossref","first-page":"3221","DOI":"10.1007\/s00213-021-05937-1","article-title":"The selective TAAR1 partial agonist RO5263397 promoted novelty recognition memory in mice","volume":"238","author":"Wu","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib116","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105571","article-title":"Role of trace amine\u2011associated receptor 1 in the medial prefrontal cortex in chronic social stress-induced cognitive deficits in mice","volume":"167","author":"Zhang","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084119","article-title":"Towards novel treatments for schizophrenia: molecular and behavioural signatures of the psychotropic agent SEP-363856","volume":"22","author":"Begni","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib118","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1017\/S1092852920002357","article-title":"Safety and effectiveness of SEP-363856 in schizophrenia: results of a 6-month, open-label extension study","volume":"26","author":"Correll","year":"2021","journal-title":"CNS Spectr."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib119","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/17460441.2018.1524459","article-title":"Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies","volume":"13","author":"Szil\u00e1gyi","year":"2018","journal-title":"Expert Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib120","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5582\/bst.2014.01034","article-title":"Evaluation of human D-amino acid oxidase inhibition by anti-psychotic drugs in vitro","volume":"8","author":"Shishikura","year":"2014","journal-title":"Biosci. Trends"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib121","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1017\/neu.2015.1","article-title":"Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine","volume":"27","author":"Matsuura","year":"2015","journal-title":"Acta Neuropsychiatr."},{"key":"10.1016\/j.phrs.2022.106078_bib122","unstructured":"Study to Evaluate Safety & Efficacy of NaBen\u00ae as Add-on Treatment for Schizophrenia in Adults, SyneuRx International (Taiwan) Corp, 2021."},{"key":"10.1016\/j.phrs.2022.106078_bib123","unstructured":"A Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacokinetics of 3 Dose Levels of TAK-831 in Adjunctive Treatment of Adult Participants With Negative Symptoms of Schizophrenia, Neurocrine Biosciences, 2021."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib124","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1038\/s41380-018-0114-5","article-title":"A dopaminergic mechanism of antipsychotic drug efficacy, failure, and failure reversal: the role of the dopamine transporter","volume":"25","author":"Amato","year":"2020","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib125","doi-asserted-by":"crossref","first-page":"42","DOI":"10.3389\/fpsyt.2017.00042","article-title":"The role of norepinephrine and Its \u03b1-adrenergic receptors in the pathophysiology and treatment of major depressive disorder and schizophrenia: a systematic review","volume":"8","author":"Maletic","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib126","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1017\/S1461145713000680","article-title":"Norepinephrine transporter occupancy in the human brain after oral administration of quetiapine XR","volume":"16","author":"Nyberg","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib127","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.neuron.2012.04.019","article-title":"Use-dependent inhibition of synaptic transmission by the secretion of intravesicularly accumulated antipsychotic drugs","volume":"74","author":"Tischbirek","year":"2012","journal-title":"Neuron"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.neuron.2012.05.013","article-title":"The best things come in small packages- vesicular delivery of weak base antipsychotics","volume":"74","author":"Morton","year":"2012","journal-title":"Neuron"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib129","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.euroneuro.2016.01.001","article-title":"The fast-off hypothesis revisited: a functional kinetic study of antipsychotic antagonism of the dopamine D2 receptor","volume":"26","author":"Sahlholm","year":"2016","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib130","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/(SICI)1097-4695(199710)33:4<395::AID-NEU5>3.0.CO;2-5","article-title":"Effects of the neurotrophins nerve growth factor, neurotrophin-3, and brain-derived neurotrophic factor (BDNF) on neurite growth from adult sensory neurons in compartmented cultures","volume":"33","author":"Kimpinski","year":"1997","journal-title":"J. Neurobiol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib131","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1017\/S0033291719001685","article-title":"Peripheral inflammatory and neurotrophic biomarkers of cognitive impairment in schizophrenia: a meta-analysis","volume":"49","author":"Bora","year":"2019","journal-title":"Psychol. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib132","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1038\/mp.2014.117","article-title":"Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications","volume":"20","author":"Fernandes","year":"2015","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib133","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S1461145711000150","article-title":"Modulation of BDNF expression by repeated treatment with the novel antipsychotic lurasidone under basal condition and in response to acute stress","volume":"15","author":"Fumagalli","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib134","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/jnr.10440","article-title":"Expression of brain-derived neurotrophic factor mRNA in rat hippocampus after treatment with antipsychotic drugs","volume":"71","author":"Bai","year":"2003","journal-title":"J. Neurosci. Res."},{"issue":"13","key":"10.1016\/j.phrs.2022.106078_bib135","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1097\/00001756-200409150-00022","article-title":"Quetiapine regulates FGF-2 and BDNF expression in the hippocampus of animals treated with MK-801","volume":"15","author":"Fumagalli","year":"2004","journal-title":"Neuroreport"},{"key":"10.1016\/j.phrs.2022.106078_bib136","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3389\/fnbeh.2019.00163","article-title":"Risperidone reverses the downregulation of BDNF in hippocampal neurons and MK801-induced cognitive impairment in rats","volume":"13","author":"Yu","year":"2019","journal-title":"Front. Behav. Neurosci."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib137","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3892\/br.2017.850","article-title":"Risperidone reverses the spatial object recognition impairment and hippocampal BDNF-TrkB signalling system alterations induced by acute MK-801 treatment","volume":"6","author":"Chen","year":"2017","journal-title":"Biomed. Rep."},{"issue":"35","key":"10.1016\/j.phrs.2022.106078_bib138","doi-asserted-by":"crossref","first-page":"21663","DOI":"10.1074\/jbc.M115.664920","article-title":"Nuclear translocation of calcium\/calmodulin-dependent protein kinase II\u03b43 promoted by protein phosphatase-1 enhances brain-derived neurotrophic factor expression in dopaminergic neurons","volume":"290","author":"Shioda","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib139","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.neures.2011.08.010","article-title":"Effects of antipsychotic drugs on BDNF, GSK-3\u03b2, and \u03b2-catenin expression in rats subjected to immobilization stress","volume":"71","author":"Park","year":"2011","journal-title":"Neurosci. Res."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/pcn.12242","article-title":"Psychopharmacology of atypical antipsychotic drugs: From the receptor binding profile to neuroprotection and neurogenesis","volume":"69","author":"Kusumi","year":"2015","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib141","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172999","article-title":"Oral quetiapine treatment results in time-dependent alterations of recognition memory and brain-derived neurotrophic factor-related signaling molecules in the hippocampus of rats","volume":"197","author":"Poddar","year":"2020","journal-title":"Pharmacol., Biochem., Behav."},{"key":"10.1016\/j.phrs.2022.106078_bib142","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172853","article-title":"Chronic oral treatment with risperidone impairs recognition memory and alters brain-derived neurotrophic factor and related signaling molecules in rats","volume":"189","author":"Poddar","year":"2020","journal-title":"Pharmacol., Biochem., Behav."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib143","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/FBP.0000000000000419","article-title":"Chronic clozapine treatment improves the alterations of prepulse inhibition and BDNF mRNA expression in the medial prefrontal cortex that are induced by adolescent social isolation","volume":"30","author":"Li","year":"2019","journal-title":"Behav. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib144","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0006-8993(02)03215-8","article-title":"Differential regulation of hippocampal BDNF mRNA by typical and atypical antipsychotic administration","volume":"954","author":"Chlan-Fourney","year":"2002","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib145","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu061","article-title":"Lurasidone exerts antidepressant properties in the chronic mild stress model through the regulation of synaptic and neuroplastic mechanisms in the rat prefrontal cortex","volume":"18","author":"Luoni","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib146","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.euroneuro.2016.12.001","article-title":"Chronic lurasidone treatment normalizes GABAergic marker alterations in the dorsal hippocampus of mice exposed to prenatal immune activation","volume":"27","author":"Luoni","year":"2017","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib147","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euroneuro.2013.12.010","article-title":"Delayed BDNF alterations in the prefrontal cortex of rats exposed to prenatal stress: preventive effect of lurasidone treatment during adolescence","volume":"24","author":"Luoni","year":"2014","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib148","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbr.2013.01.032","article-title":"Ziprasidone ameliorates anxiety-like behaviors in a rat model of PTSD and up-regulates neurogenesis in the hippocampus and hippocampus-derived neural stem cells","volume":"244","author":"Peng","year":"2013","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib149","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2017.120","article-title":"The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression","volume":"7","author":"Morais","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib150","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.biopsych.2004.07.008","article-title":"Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat","volume":"56","author":"Kodama","year":"2004","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib151","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193156","article-title":"Clozapine protects adult neural stem cells from ketamine-induced cell death in correlation with decreased apoptosis and autophagy","volume":"40","author":"Lundberg","year":"2020","journal-title":"Biosci. Rep."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib152","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.pbb.2011.03.011","article-title":"Putative cognitive enhancers in preclinical models related to schizophrenia: the search for an elusive target","volume":"99","author":"Barak","year":"2011","journal-title":"Pharmacol., Biochem., Behav."},{"key":"10.1016\/j.phrs.2022.106078_bib153","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1007\/s43440-021-00259-7","article-title":"Chlorpromazine affects the numbers of Sox-2, Musashi1 and DCX-expressing cells in the rat brain subventricular zone","volume":"73","author":"Ska\u0142bania","year":"2021","journal-title":"Pharmacol. Rep.: PR"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib154","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1038\/sj.npp.1300422","article-title":"Effects of chronic haloperidol and clozapine treatment on neurogenesis in the adult rat hippocampus","volume":"29","author":"Halim","year":"2004","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib155","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.schres.2014.04.041","article-title":"Neuroinflammation and white matter pathology in schizophrenia: systematic review","volume":"161","author":"Najjar","year":"2015","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib156","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1017\/S1461145707007730","article-title":"Compromised myelin integrity during psychosis with repair during remission in drug-responding schizophrenia","volume":"11","author":"Garver","year":"2008","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib157","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.brainres.2009.09.084","article-title":"Cuprizone effect on myelination, astrogliosis and microglia attraction in the mouse basal ganglia","volume":"1305","author":"Pott","year":"2009","journal-title":"Brain Res."},{"key":"10.1016\/j.phrs.2022.106078_bib158","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.neuint.2018.04.001","article-title":"The antipsychotic drug quetiapine stimulates oligodendrocyte differentiation by modulating the cell cycle","volume":"118","author":"Mi","year":"2018","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.phrs.2022.106078_bib159","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.neuint.2015.08.015","article-title":"The cuprizone-induced changes in (1)H-MRS metabolites and oxidative parameters in C57BL\/6 mouse brain: effects of quetiapine","volume":"90","author":"Xuan","year":"2015","journal-title":"Neurochem. Int."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib160","doi-asserted-by":"crossref","first-page":"pyv088","DOI":"10.1093\/ijnp\/pyv088","article-title":"Quetiapine ameliorates schizophrenia-like behaviors and protects myelin integrity in cuprizone intoxicated mice: the involvement of Notch Signaling Pathway","volume":"19","author":"Wang","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib161","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/sj.mp.4002064","article-title":"Quetiapine facilitates oligodendrocyte development and prevents mice from myelin breakdown and behavioral changes","volume":"13","author":"Xiao","year":"2008","journal-title":"Mol. Psychiatry"},{"issue":"5415","key":"10.1016\/j.phrs.2022.106078_bib162","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1126\/science.284.5415.770","article-title":"Notch signaling: cell fate control and signal integration in development","volume":"284","author":"Artavanis-Tsakonas","year":"1999","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib163","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0092-8674(03)00810-9","article-title":"F3\/contactin acts as a functional ligand for Notch during oligodendrocyte maturation","volume":"115","author":"Hu","year":"2003","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2022.106078_bib164","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neuroscience.2011.10.051","article-title":"Magnetic resonance imaging and histological evidence for the blockade of cuprizone-induced demyelination in C57BL\/6 mice","volume":"202","author":"Chandran","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.phrs.2022.106078_bib165","doi-asserted-by":"crossref","first-page":"843","DOI":"10.3389\/fpsyt.2020.00843","article-title":"Quetiapine attenuates schizophrenia-like behaviors and demyelination in a MK-801-induced mouse model of schizophrenia","volume":"11","author":"He","year":"2020","journal-title":"Front. Psychiatry"},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib166","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41398-017-0008-3","article-title":"Subchronic olanzapine exposure leads to increased expression of myelination-related genes in rat fronto-medial cortex","volume":"7","author":"Ersland","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib167","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.psychres.2014.02.019","article-title":"Olanzapine ameliorates neuropathological changes and increases IGF-1 expression in frontal cortex of C57BL\/6 mice exposed to cuprizone","volume":"216","author":"Zhang","year":"2014","journal-title":"Psychiatry Res."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib168","article-title":"Behavioral and neurobiological changes in C57BL\/6 mouse exposed to cuprizone: effects of antipsychotics","volume":"4","author":"Xu","year":"2010","journal-title":"Front. Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib169","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00441-006-0274-5","article-title":"The postsynaptic density","volume":"326","author":"Boeckers","year":"2006","journal-title":"Cell Tissue Res."},{"key":"10.1016\/j.phrs.2022.106078_bib170","doi-asserted-by":"crossref","first-page":"240","DOI":"10.3389\/fnbeh.2017.00240","article-title":"Immediate-early genes modulation by antipsychotics: translational implications for a putative gateway to drug-induced long-term brain changes","volume":"11","author":"de Bartolomeis","year":"2017","journal-title":"Front. Behav. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib171","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0306-4522(92)90054-6","article-title":"Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine","volume":"46","author":"Robertson","year":"1992","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib172","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1016\/j.euroneuro.2012.11.014","article-title":"Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol","volume":"23","author":"de Bartolomeis","year":"2013","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib173","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1017\/S1461145714000042","article-title":"Changes in brain functional connectivity after chronic haloperidol in rats: a network analysis","volume":"17","author":"Wheeler","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib174","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113160","article-title":"Modulation of glutamatergic functional connectivity by a prototypical antipsychotic: Translational inference from a postsynaptic density immediate-early gene-based network analysis","volume":"404","author":"Barone","year":"2021","journal-title":"Behav. Brain Res."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib175","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00213-020-05498-9","article-title":"Chronic treatment with the antipsychotic drug blonanserin modulates the responsiveness to acute stress with anatomical selectivity","volume":"237","author":"Marchisella","year":"2020","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib176","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00213-012-2900-0","article-title":"Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid","volume":"226","author":"Calabrese","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib177","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2013.11.008","article-title":"Repeated aripiprazole treatment regulates Bdnf, Arc and Npas4 expression under basal condition as well as after an acute swim stress in the rat brain","volume":"80","author":"Luoni","year":"2014","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib178","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.pnpbp.2013.12.008","article-title":"Anatomical specificity in the modulation of activity-regulated genes after acute or chronic lurasidone treatment","volume":"50","author":"Luoni","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"15","key":"10.1016\/j.phrs.2022.106078_bib179","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21155555","article-title":"The effects of antipsychotics on the synaptic plasticity gene Homer1a depend on a combination of their receptor profile, dose, duration of treatment, and brain regions targeted","volume":"21","author":"Iasevoli","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106078_bib180","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpsychires.2019.06.009","article-title":"Gray matter volume changes following antipsychotic therapy in first-episode schizophrenia patients: a longitudinal voxel-based morphometric study","volume":"116","author":"Guo","year":"2019","journal-title":"J. Psychiatr. Res."},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib181","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1017\/S0033291717000642","article-title":"Brain volume changes over the first year of treatment in schizophrenia: relationships to antipsychotic treatment","volume":"47","author":"Emsley","year":"2017","journal-title":"Psychol. Med."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib182","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118510","article-title":"Temporal and spatial transcriptional fingerprints by antipsychotic or propsychotic drugs in mouse brain","volume":"10","author":"Sakuma","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106078_bib183","article-title":"Antipsychotics effects on network-level reconfiguration of cortical morphometry in first-episode schizophrenia","author":"Jiang","year":"2021","journal-title":"Schizophr. Bull."},{"issue":"23","key":"10.1016\/j.phrs.2022.106078_bib184","article-title":"The postsynaptic density: there is more than meets the eye","volume":"8","author":"Dosemeci","year":"2016","journal-title":"Front. Synaptic Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib185","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/jb\/mvy022","article-title":"Postsynaptic density proteins and their involvement in neurodevelopmental disorders","volume":"163","author":"Kaizuka","year":"2018","journal-title":"J. Biochem."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib186","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1136\/jnnp.65.4.446","article-title":"Reduced dendritic spine density on cerebral cortical pyramidal neurons in schizophrenia","volume":"65","author":"Garey","year":"1998","journal-title":"J. Neurol., Neurosurg., Psychiatry"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib187","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archpsyc.57.1.65","article-title":"Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia","volume":"57","author":"Glantz","year":"2000","journal-title":"Arch. Gen. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib188","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/npp.2008.67","article-title":"Reduced dendritic spine density in auditory cortex of subjects with schizophrenia","volume":"34","author":"Sweet","year":"2009","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib189","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.euroneuro.2018.03.004","article-title":"Effects of the antipsychotics haloperidol, clozapine, and aripiprazole on the dendritic spine","volume":"28","author":"Takaki","year":"2018","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib190","doi-asserted-by":"crossref","first-page":"9.55.1","DOI":"10.1002\/cpns.15","article-title":"The Neonatal Ventral Hippocampal Lesion (NVHL) rodent model of schizophrenia","volume":"77","author":"Brady","year":"2016","journal-title":"Curr. Protoc. Neurosci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib191","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.neuroscience.2005.02.021","article-title":"Alterations in dendritic morphology of prefrontal cortical and nucleus accumbens neurons in post-pubertal rats after neonatal excitotoxic lesions of the ventral hippocampus","volume":"133","author":"Flores","year":"2005","journal-title":"Neuroscience"},{"issue":"43","key":"10.1016\/j.phrs.2022.106078_bib192","doi-asserted-by":"crossref","first-page":"8584","DOI":"10.1523\/JNEUROSCI.1249-19.2019","article-title":"Risperidone ameliorates prefrontal cortex neural atrophy and oxidative\/nitrosative stress in brain and peripheral blood of rats with neonatal ventral hippocampus lesion","volume":"39","author":"Tendilla-Beltr\u00e1n","year":"2019","journal-title":"J. Neurosci.: Off. J. Soc. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib193","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.neubiorev.2019.08.019","article-title":"Translating preclinical findings in clinically relevant new antipsychotic targets: focus on the glutamatergic postsynaptic density. Implications for treatment resistant schizophrenia","volume":"107","author":"de Bartolomeis","year":"2019","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib194","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.euroneuro.2018.01.006","article-title":"Nicotine and caffeine modulate haloperidol-induced changes in postsynaptic density transcripts expression: translational insights in psychosis therapy and treatment resistance","volume":"28","author":"de Bartolomeis","year":"2018","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106078_bib195","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.psychres.2010.02.009","article-title":"Haloperidol induces higher Homer1a expression than risperidone, olanzapine and sulpiride in striatal sub-regions","volume":"177","author":"Iasevoli","year":"2010","journal-title":"Psychiatry Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib196","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18010135","article-title":"Bartolomeis, treating the synapse in major psychiatric disorders: the role of postsynaptic density network in dopamine-glutamate interplay and psychopharmacologic drugs molecular actions","volume":"18","author":"Tomasetti","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2022.106078_bib197","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejphar.2013.06.034","article-title":"Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment","volume":"718","author":"de Bartolomeis","year":"2013","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib198","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/syn.20385","article-title":"Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain","volume":"61","author":"Ambesi-Impiombato","year":"2007","journal-title":"Synapse"},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib199","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0269881109358199","article-title":"Pattern of acute induction of Homer1a gene is preserved after chronic treatment with first- and second-generation antipsychotics: effect of short-term drug discontinuation and comparison with Homer1a-interacting genes","volume":"25","author":"Iasevoli","year":"2011","journal-title":"J. Psychopharmacology"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib200","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.euroneuro.2015.01.003","article-title":"Progressive recruitment of cortical and striatal regions by inducible postsynaptic density transcripts after increasing doses of antipsychotics with different receptor profiles: insights for psychosis treatment","volume":"25","author":"de Bartolomeis","year":"2015","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib201","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00213-010-1954-0","article-title":"Divergent acute and chronic modulation of glutamatergic postsynaptic density genes expression by the antipsychotics haloperidol and sertindole","volume":"212","author":"Iasevoli","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib202","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pnpbp.2013.06.010","article-title":"Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis","volume":"46","author":"de Bartolomeis","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib203","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.pnpbp.2016.04.015","article-title":"Switching antipsychotics: Imaging the differential effect on the topography of postsynaptic density transcripts in antipsychotic-na\u00efve vs. antipsychotic-exposed rats","volume":"70","author":"de Bartolomeis","year":"2016","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib204","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.phrs.2011.05.026","article-title":"A neurochemical basis for an epigenetic vision of psychiatric disorders (1994-2009)","volume":"64","author":"Guidotti","year":"2011","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib205","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2012.86","article-title":"Upregulation of TET1 and downregulation of APOBEC3A and APOBEC3C in the parietal cortex of psychotic patients","volume":"2","author":"Dong","year":"2012","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib206","doi-asserted-by":"crossref","first-page":"721","DOI":"10.2217\/epi-2016-0106","article-title":"Understanding epigenetics of schizophrenia in the backdrop of its antipsychotic drug therapy","volume":"9","author":"Swathy","year":"2017","journal-title":"Epigenomics"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib207","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41386-018-0143-4","article-title":"Chronic clozapine treatment restrains via HDAC2 the performance of mGlu2 receptor agonism in a rodent model of antipsychotic activity","volume":"44","author":"de la Fuente Revenga","year":"2019","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib208","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ajmg.b.32361","article-title":"Antipsychotic drugs attenuate aberrant DNA methylation of DTNBP1 (dysbindin) promoter in saliva and post-mortem brain of patients with schizophrenia and Psychotic bipolar disorder","volume":"168","author":"Abdolmaleky","year":"2015","journal-title":"Am. J. Med. Genet. Part B, Neuropsychiatr. Genet.: Off. Publ. Int. Soc. Psychiatr. Genet."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib209","doi-asserted-by":"crossref","first-page":"233","DOI":"10.2217\/epi-2017-0086","article-title":"Understanding the influence of antipsychotic drugs on global methylation events and its relevance in treatment response","volume":"10","author":"Swathy","year":"2018","journal-title":"Epigenomics"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib210","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1124\/mol.118.113415","article-title":"N-Phthalyl-l-Tryptophan (RG108), like Clozapine (CLO), induces chromatin remodeling in brains of prenatally stressed mice","volume":"95","author":"Dong","year":"2019","journal-title":"Mol. Pharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib211","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2015.191","article-title":"Behavioral and molecular neuroepigenetic alterations in prenatally stressed mice: relevance for the study of chromatin remodeling properties of antipsychotic drugs","volume":"6","author":"Dong","year":"2016","journal-title":"Transl. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib212","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1017\/S1461145713001466","article-title":"Clozapine ameliorates epigenetic and behavioral abnormalities induced by phencyclidine through activation of dopamine D1 receptor","volume":"17","author":"Aoyama","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib213","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2049-9256-1-19","article-title":"Olanzapine induced DNA methylation changes support the dopamine hypothesis of psychosis","volume":"1","author":"Melka","year":"2013","journal-title":"J. Mol. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib214","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1471-2202-15-112","article-title":"Olanzapine-induced methylation alters cadherin gene families and associated pathways implicated in psychosis","volume":"15","author":"Melka","year":"2014","journal-title":"BMC Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1868-7083-6-1","article-title":"The effects of olanzapine on genome-wide DNA methylation in the hippocampus and cerebellum","volume":"6","author":"Melka","year":"2014","journal-title":"Clin. Epigenetics"},{"key":"10.1016\/j.phrs.2022.106078_bib216","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/2682037","article-title":"Effects of antipsychotic drugs on the epigenetic modification of brain-derived neurotrophic factor gene expression in the hippocampi of chronic restraint stress rats","volume":"2018","author":"Seo","year":"2018","journal-title":"Neural Plast."},{"key":"10.1016\/j.phrs.2022.106078_bib217","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.pnpbp.2014.08.010","article-title":"Effects of quetiapine on DNA methylation in neuroblastoma cells","volume":"56","author":"Sugawara","year":"2015","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib218","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184209","article-title":"Haloperidol induces pharmacoepigenetic response by modulating miRNA expression, global DNA methylation and expression profiles of methylation maintenance genes and genes involved in neurotransmission in neuronal cells","volume":"12","author":"Swathy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106078_bib219","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.neulet.2014.01.038","article-title":"Comprehensive DNA methylation analysis of human neuroblastoma cells treated with blonanserin","volume":"563","author":"Murata","year":"2014","journal-title":"Neurosci. Lett."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib220","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1096\/fj.11-202069","article-title":"Epigenetic aberrations in leukocytes of patients with schizophrenia: association of global DNA methylation with antipsychotic drug treatment and disease onset","volume":"26","author":"Melas","year":"2012","journal-title":"FASEB J.: Off. Publ. Fed. Am. Soc. Exp. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib221","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/cei.13250","article-title":"Risperidone effects on heterochromatin: the role of kinase signaling","volume":"196","author":"Feiner","year":"2019","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.phrs.2022.106078_bib222","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2020.100271","article-title":"Long-term effects of stress early in life on microRNA-30a and its network: Preventive effects of lurasidone and potential implications for depression vulnerability","volume":"13","author":"Cattaneo","year":"2020","journal-title":"Neurobiol. Stress"},{"key":"10.1016\/j.phrs.2022.106078_bib223","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2016.07.006","article-title":"MicroRNAs and psychiatric disorders: from aetiology to treatment","volume":"167","author":"Luoni","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib224","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126197","article-title":"Stress modifies the expression of glucocorticoid-responsive genes by acting at epigenetic levels in the rat prefrontal cortex: modulatory activity of lurasidone","volume":"22","author":"Brivio","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib225","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.tips.2008.10.010","article-title":"Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling","volume":"30","author":"Guidotti","year":"2009","journal-title":"Trends Pharmacol. Sci."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib226","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/schbul\/sby024","article-title":"Inflammation in schizophrenia: pathogenetic aspects and therapeutic considerations","volume":"44","author":"M\u00fcller","year":"2018","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.phrs.2022.106078_bib227","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3389\/fpsyt.2019.00892","article-title":"Cytokine alterations in schizophrenia: an updated review","volume":"10","author":"Momtazmanesh","year":"2019","journal-title":"Front. Psychiatry"},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib228","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1007\/s40263-020-00765-x","article-title":"Effects of antipsychotic drugs: cross talk between the nervous and innate immune system","volume":"34","author":"Dinesh","year":"2020","journal-title":"CNS Drugs"},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib229","doi-asserted-by":"crossref","first-page":"8140","DOI":"10.1007\/s12035-016-0280-x","article-title":"Neuroprotection by chlorpromazine and promethazine in severe transient and permanent ischemic stroke","volume":"54","author":"Geng","year":"2017","journal-title":"Mol. Neurobiol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib230","doi-asserted-by":"crossref","first-page":"232","DOI":"10.2174\/1567202616666190624122727","article-title":"Artificial hibernation by phenothiazines: a potential neuroprotective therapy against cerebral inflammation in stroke","volume":"16","author":"Guan","year":"2019","journal-title":"Curr. Neurovascular Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib231","first-page":"247","article-title":"Inhibitory effect of antipsychotic drugs on the Con A- and LPS-induced proliferative activity of mouse splenocytes: a possible mechanism of action","volume":"57","author":"Basta-Kaim","year":"2006","journal-title":"J. Physiol. Pharmacol.: Off. J. Pol. Physiol. Soc."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib232","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1002\/jnr.20488","article-title":"Microglial cell activation and proliferation precedes the onset of CNS autoimmunity","volume":"81","author":"Ponomarev","year":"2005","journal-title":"J. Neurosci. Res."},{"issue":"13","key":"10.1016\/j.phrs.2022.106078_bib233","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1017\/S0033291718003057","article-title":"Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies","volume":"49","author":"Marques","year":"2019","journal-title":"Psychol. Med."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib234","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/j.biopsych.2008.04.025","article-title":"Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study","volume":"64","author":"van Berckel","year":"2008","journal-title":"Biol. Psychiatry"},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib235","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/jcbfm.2015.128","article-title":"De novo expression of dopamine D2 receptors on microglia after stroke","volume":"35","author":"Huck","year":"2015","journal-title":"J. Cereb. Blood Flow. Metab.: Off. J. Int. Soc. Cereb. Blood Flow. Metab."},{"key":"10.1016\/j.phrs.2022.106078_bib236","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656941","article-title":"Clozapine regulates microglia and is effective in chronic experimental autoimmune encephalomyelitis","volume":"12","author":"Ceylan","year":"2021","journal-title":"Front. Immunol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib237","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094399","article-title":"Effects of haloperidol, risperidone, and aripiprazole on the immunometabolic properties of BV-2 microglial cells","volume":"22","author":"Racki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2022.106078_bib238","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173411","article-title":"Amisulpride alleviates chronic mild stress-induced cognitive deficits: Role of prefrontal cortex microglia and Wnt\/\u03b2-catenin pathway","volume":"885","author":"Mohamed","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib239","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042746","article-title":"Quetiapine, an atypical antipsychotic, is protective against autoimmune-mediated demyelination by inhibiting effector T cell proliferation","volume":"7","author":"Mei","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106078_bib240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.cyto.2017.04.004","article-title":"Different influence of antipsychotics on the balance between pro- and anti-inflammatory cytokines depends on glia activation: an in vitro study","volume":"94","author":"Obuchowicz","year":"2017","journal-title":"Cytokine"},{"key":"10.1016\/j.phrs.2022.106078_bib241","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbi.2016.12.011","article-title":"Antipsychotics influence Toll-like receptor (TLR) expression and its relationship with cognitive functions in schizophrenia","volume":"62","author":"K\u00e9ri","year":"2017","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib242","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyu070","article-title":"Paliperidone prevents brain toll-like receptor 4 pathway activation and neuroinflammation in rat models of acute and chronic restraint stress","volume":"18","author":"MacDowell","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib243","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.neuropharm.2016.12.025","article-title":"Paliperidone reverts Toll-like receptor 3 signaling pathway activation and cognitive deficits in a maternal immune activation mouse model of schizophrenia","volume":"116","author":"MacDowell","year":"2017","journal-title":"Neuropharmacology"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib244","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s11481-019-09860-3","article-title":"Haloperidol reduces the activity of complement and induces the anti-inflammatory transformation of peritoneal macrophages in rats","volume":"14","author":"Cheremnykh","year":"2019","journal-title":"J. NeuroImmune Pharmacol.: Off. J. Soc. NeuroImmune Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106078_bib245","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.imlet.2011.06.011","article-title":"Antipsychotic drugs suppress the AKT\/NF-\u03baB pathway and regulate the differentiation of T-cell subsets","volume":"140","author":"Chen","year":"2011","journal-title":"Immunol. Lett."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib246","doi-asserted-by":"crossref","first-page":"686","DOI":"10.3109\/08923973.2011.651535","article-title":"Clozapine inhibits Th1cell differentiation and causes the suppression of IFN-\u03b3 production in peripheral blood mononuclear cells","volume":"34","author":"Chen","year":"2012","journal-title":"Immunopharmacol. Immunotoxicol."},{"key":"10.1016\/j.phrs.2022.106078_bib247","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ncomms2260","article-title":"T-bet and GATA3 orchestrate Th1 and Th2 differentiation through lineage-specific targeting of distal regulatory elements","volume":"3","author":"Kanhere","year":"2012","journal-title":"Nat. Commun."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib248","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1213\/ANE.0000000000000606","article-title":"Haloperidol suppresses murine dendritic cell maturation and priming of the T helper 1-type immune response","volume":"120","author":"Matsumoto","year":"2015","journal-title":"Anesth. Analg."},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib249","doi-asserted-by":"crossref","DOI":"10.1038\/tp.2016.238","article-title":"Cortical grey matter volume reduction in people with schizophrenia is associated with neuro-inflammation","volume":"6","author":"Zhang","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib250","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/1567179","article-title":"Quetiapine attenuates the neuroinflammation and executive function deficit in streptozotocin-induced diabetic mice","volume":"2019","author":"Wang","year":"2019","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.phrs.2022.106078_bib251","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2015.10.022","article-title":"Stress-induced anhedonia is associated with the activation of the inflammatory system in the rat brain: Restorative effect of pharmacological intervention","volume":"103","author":"Rossetti","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib252","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1089\/088282403322017884","article-title":"The hypothalamic-pituitary-adrenal axis and viral infection","volume":"16","author":"Bailey","year":"2003","journal-title":"Viral Immunol."},{"key":"10.1016\/j.phrs.2022.106078_bib253","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172978","article-title":"Atypical antipsychotic drug modulates early life infection induced impairment of hypothalamic-pituitary-adrenal axis: an age related study in mice","volume":"872","author":"Gupta","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib254","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.pbb.2015.05.021","article-title":"The effect of the antipsychotic drug quetiapine and its metabolite norquetiapine on acute inflammation, memory and anhedonia","volume":"135","author":"Jaehne","year":"2015","journal-title":"Pharmacol., Biochem., Behav."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib255","first-page":"69","article-title":"Protective effects of quetiapine on metabolic and inflammatory abnormalities in schizophrenic patients during exacerbated stage","volume":"59","author":"Kao","year":"2016","journal-title":"Chin. J. Physiol."},{"key":"10.1016\/j.phrs.2022.106078_bib256","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.bbi.2015.08.003","article-title":"Disruptions of sensorimotor gating, cytokines, glycemia, monoamines, and genes in both sexes of rats reared in social isolation can be ameliorated by oral chronic quetiapine administration","volume":"51","author":"Ko","year":"2016","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib257","doi-asserted-by":"crossref","DOI":"10.3390\/cells9030577","article-title":"Clozapine prevents poly (I:C) induced inflammation by modulating NLRP3 pathway in microglial cells","volume":"9","author":"Giridharan","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.phrs.2022.106078_bib258","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jpsychires.2018.08.017","article-title":"Second generation atypical antipsychotics olanzapine and aripiprazole reduce expression and secretion of inflammatory cytokines in human immune cells","volume":"105","author":"Stapel","year":"2018","journal-title":"J. Psychiatr. Res."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib259","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00213-021-05824-9","article-title":"Do proinflammatory cytokines play a role in clozapine-associated glycometabolism disorders?","volume":"238","author":"Zhao","year":"2021","journal-title":"Psychopharmacology"},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib260","doi-asserted-by":"crossref","DOI":"10.3390\/jpm11111189","article-title":"Long term metabolic and inflammatory effects of second-generation antipsychotics: a study in mentally disordered offenders","volume":"11","author":"Vassilopoulou","year":"2021","journal-title":"J. Pers. Med."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib261","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1038\/s41598-018-36930-y","article-title":"Chronic olanzapine administration causes metabolic syndrome through inflammatory cytokines in rodent models of insulin resistance","volume":"9","author":"Li","year":"2019","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib262","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0218937","article-title":"The antipsychotic medication, risperidone, causes global immunosuppression in healthy mice","volume":"14","author":"May","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.phrs.2022.106078_bib263","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jpsychires.2018.11.008","article-title":"Immunomodulatory effects of antipsychotic treatment on gene expression in first-episode psychosis","volume":"109","author":"Mantere","year":"2019","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib264","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01616412.2021.1910904","article-title":"Chlorpromazine and promethazine reduces Brain injury through RIP1-RIP3 regulated activation of NLRP3 inflammasome following ischemic stroke","volume":"43","author":"Jiang","year":"2021","journal-title":"Neurol. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib265","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib266","doi-asserted-by":"crossref","first-page":"12471","DOI":"10.1038\/s41598-018-30763-5","article-title":"Repurposing Thioridazine (TDZ) as an anti-inflammatory agent","volume":"8","author":"Baig","year":"2018","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib267","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.neubiorev.2010.10.008","article-title":"Oxidative stress in schizophrenia: an integrated approach","volume":"35","author":"Bitanihirwe","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2022.106078_bib268","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.3389\/fphar.2019.01517","article-title":"Pimozide inhibits the human prostate cancer cells through the generation of reactive oxygen species","volume":"10","author":"Kim","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107520","article-title":"Oxidation-reduction mechanisms in psychiatric disorders: a novel target for pharmacological intervention","volume":"210","author":"Rossetti","year":"2020","journal-title":"Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib270","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.vph.2014.01.008","article-title":"Asenapine increases nitric oxide release and protects porcine coronary artery endothelial cells against peroxidation","volume":"60","author":"Grossini","year":"2014","journal-title":"Vasc. Pharmacol."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib271","doi-asserted-by":"crossref","first-page":"171","DOI":"10.4103\/0019-5545.43627","article-title":"A comparative study of oxidative stress and interrelationship of important antioxidants in haloperidol and olanzapine treated patients suffering from schizophrenia","volume":"50","author":"Singh","year":"2008","journal-title":"Indian J. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib272","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1176\/jnp.17.2.227","article-title":"Oxidative stress during treatment with first- and second-generation antipsychotics","volume":"17","author":"Kropp","year":"2005","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib273","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1007\/s13311-016-0438-2","article-title":"The atypical antipsychotic paliperidone regulates endogenous antioxidant\/anti-inflammatory pathways in rat models of acute and chronic restraint stress","volume":"13","author":"MacDowell","year":"2016","journal-title":"Neurother.: J. Am. Soc. Exp. Neurother."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib274","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.euroneuro.2019.05.002","article-title":"Risperidone administered during adolescence induced metabolic, anatomical and inflammatory\/oxidative changes in adult brain: A PET and MRI study in the maternal immune stimulation animal model","volume":"29","author":"Casquero-Veiga","year":"2019","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.2272","article-title":"Effect of atypical antipsychotics on antioxidant enzyme activities in human erythrocytes (in vitro study)","volume":"28","author":"Miljevi\u0107","year":"2013","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib276","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fpsyt.2018.00501","article-title":"Hydrogen sulfide affects radical formation in the hippocampus of LPS treated rats and the effect of antipsychotics on hydrogen sulfide forming enzymes in human cell lines","volume":"9","author":"Sommer","year":"2018","journal-title":"Front. Psychiatry"},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib277","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/pcn.12631","article-title":"Comparative effects of aripiprazole and selected antipsychotic drugs on lipid peroxidation in plasma","volume":"72","author":"Dietrich-Muszalska","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib278","doi-asserted-by":"crossref","first-page":"555","DOI":"10.2147\/NDT.S283395","article-title":"Comparative study of the effects of atypical antipsychotic drugs on plasma and urine biomarkers of oxidative stress in schizophrenic patients","volume":"17","author":"Dietrich-Muszalska","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib279","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00406-013-0414-3","article-title":"Differential effects of antipsychotics on the development of rat oligodendrocyte precursor cells exposed to cuprizone","volume":"264","author":"Xu","year":"2014","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib280","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.biopha.2016.02.047","article-title":"Clozapine and olanzapine are better antioxidants than haloperidol, quetiapine, risperidone and ziprasidone in in vitro models","volume":"81","author":"Brinholi","year":"2016","journal-title":"Biomed. Pharmacother. = Biomedecine Pharmacother."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib281","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1080\/10715762.2019.1572889","article-title":"Antipsychotic drugs scavenge radiation-induced hydroxyl radicals and intracellular ROS formation, and protect apoptosis in human lymphoma U937 cells","volume":"53","author":"Zhao","year":"2019","journal-title":"Free Radic. Res."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib282","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1089\/ars.2010.3453","article-title":"Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia","volume":"15","author":"Matsuzawa","year":"2011","journal-title":"Antioxid. Redox Signal."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib283","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1093\/ijnp\/pyy046","article-title":"Chronic stress exposure reduces parvalbumin expression in the rat hippocampus through an imbalance of redox mechanisms: restorative effect of the antipsychotic lurasidone","volume":"21","author":"Rossetti","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib284","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105330","article-title":"Behavioral and molecular effects of the antipsychotic drug blonanserin in the chronic mild stress model","volume":"163","author":"Paladini","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib285","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/schbul\/sbq113","article-title":"Progressive structural brain changes during development of psychosis","volume":"38","author":"Ziermans","year":"2012","journal-title":"Schizophr. Bull."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib286","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.neubiorev.2013.06.001","article-title":"Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies","volume":"37","author":"Fusar-Poli","year":"2013","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib287","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1016\/j.neubiorev.2012.07.012","article-title":"Multimodal meta-analysis of structural and functional brain changes in first episode psychosis and the effects of antipsychotic medication","volume":"36","author":"Radua","year":"2012","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.phrs.2022.106078_bib288","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/1471-244X-13-342","article-title":"Structural brain changes associated with antipsychotic treatment in schizophrenia as revealed by voxel-based morphometric MRI: an activation likelihood estimation meta-analysis","volume":"13","author":"Torres","year":"2013","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib289","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.neuroimage.2018.04.054","article-title":"Regional brain volume changes following chronic antipsychotic administration are mediated by the dopamine D2 receptor","volume":"176","author":"Guma","year":"2018","journal-title":"NeuroImage"},{"key":"10.1016\/j.phrs.2022.106078_bib290","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pscychresns.2018.10.001","article-title":"Association between olanzapine treatment and brain cortical thickness and gray\/white matter contrast is moderated by cholesterol in psychotic disorders","volume":"282","author":"Gjerde","year":"2018","journal-title":"Psychiatry Res. Neuroimaging"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib291","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/acps.12677","article-title":"Brain volume change in first-episode psychosis: an effect of antipsychotic medication independent of BMI change","volume":"135","author":"J\u00f8rgensen","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib292","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.biopsych.2018.04.023","article-title":"Cortical brain abnormalities in 4474 individuals with schizophrenia and 5098 control subjects via the enhancing neuro imaging genetics through meta analysis (ENIGMA) consortium","volume":"84","author":"van Erp","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib293","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1001\/archgenpsychiatry.2010.199","article-title":"Long-term antipsychotic treatment and brain volumes: a longitudinal study of first-episode schizophrenia","volume":"68","author":"Ho","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib294","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2021.113772","article-title":"White matter microstructure and structural networks in treatment-resistant schizophrenia patients after commencing clozapine treatment: a longitudinal diffusion imaging study","volume":"298","author":"Tronchin","year":"2021","journal-title":"Psychiatry Res."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib295","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1002\/jmri.27028","article-title":"Functional alterations of white matter in chronic never-treated and treated schizophrenia patients","volume":"52","author":"Yang","year":"2020","journal-title":"J. Magn. Reson. Imaging.: JMRI"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib296","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s00406-010-0182-2","article-title":"Optimized voxel brain morphometry: association between brain volumes and the response to atypical antipsychotics","volume":"261","author":"Molina","year":"2011","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib297","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00406-015-0650-9","article-title":"First- and second-generation antipsychotic drug treatment and subcortical brain morphology in schizophrenia","volume":"266","author":"J\u00f8rgensen","year":"2016","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib298","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.schres.2019.04.002","article-title":"Antipsychotic treatment and basal ganglia volumes: exploring the role of receptor occupancy, dosage and remission status","volume":"208","author":"Di Sero","year":"2019","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib299","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2574","article-title":"Long-term antipsychotic use and brain changes in schizophrenia \u2013 a systematic review and meta-analysis","volume":"32","author":"Huhtaniska","year":"2017","journal-title":"Hum. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib300","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.schres.2012.07.014","article-title":"Effect of antipsychotic drugs on cortical thickness. A randomized controlled one-year follow-up study of haloperidol, risperidone and olanzapine","volume":"141","author":"Roiz-Santi\u00e1\u00f1ez","year":"2012","journal-title":"Schizophr. Res."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib301","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1017\/S0033291718001198","article-title":"Cortical structures and their clinical correlates in antipsychotic-na\u00efve schizophrenia patients before and after 6 weeks of dopamine D2\/3 receptor antagonist treatment","volume":"49","author":"Jessen","year":"2019","journal-title":"Psychol. Med."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib302","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1001\/jamapsychiatry.2014.2178","article-title":"A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia","volume":"72","author":"Lesh","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2022.106078_bib303","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.schres.2015.06.016","article-title":"Longitudinal regional brain volume loss in schizophrenia: relationship to antipsychotic medication and change in social function","volume":"168","author":"Guo","year":"2015","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib304","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1093\/cercor\/bhu018","article-title":"The genetic association between neocortical volume and general cognitive ability is driven by global surface area rather than thickness","volume":"25","author":"Vuoksimaa","year":"2015","journal-title":"Cereb. Cortex"},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib305","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1038\/s41386-020-0665-4","article-title":"Progressive subcortical volume loss in treatment-resistant schizophrenia patients after commencing clozapine treatment","volume":"45","author":"Tronchin","year":"2020","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.phrs.2022.106078_bib306","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.schres.2014.06.042","article-title":"Greater clinical and cognitive improvement with clozapine and risperidone associated with a thinner cortex at baseline in first-episode schizophrenia","volume":"158","author":"Molina","year":"2014","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib307","first-page":"89","article-title":"Schizophrenia: a disconnection syndrome?","volume":"3","author":"Friston","year":"1995","journal-title":"Clin. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib308","doi-asserted-by":"crossref","first-page":"34287","DOI":"10.1038\/srep34287","article-title":"Short-term effects of risperidone monotherapy on spontaneous brain activity in first-episode treatment-na\u00efve schizophrenia patients: a longitudinal fMRI study","volume":"6","author":"Hu","year":"2016","journal-title":"Sci. Rep."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106078_bib309","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.schres.2014.03.033","article-title":"Disrupted resting-state functional connectivity in minimally treated chronic schizophrenia","volume":"156","author":"Wang","year":"2014","journal-title":"Schizophr. Res."},{"issue":"sup3","key":"10.1016\/j.phrs.2022.106078_bib310","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1080\/15622975.2017.1346280","article-title":"Treatment effects of olanzapine on homotopic connectivity in drug-free schizophrenia at rest","volume":"19","author":"Guo","year":"2018","journal-title":"World J. Biol. Psychiatry: Off. J. World Fed. Soc. Biol. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib311","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.euroneuro.2020.04.008","article-title":"Region-specific effects of acute haloperidol in the human midbrain, striatum and cortex","volume":"35","author":"W\u00e4chtler","year":"2020","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib312","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/npp.2013.305","article-title":"Ventral tegmental area\/midbrain functional connectivity and response to antipsychotic medication in schizophrenia","volume":"39","author":"Hadley","year":"2014","journal-title":"Neuropsychopharmacol.: Off. Publ. Am. Coll. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2022.106078_bib313","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1017\/S1461145713000643","article-title":"Disruption of thalamocortical activity in schizophrenia models: relevance to antipsychotic drug action","volume":"16","author":"Celada","year":"2013","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib314","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.euroneuro.2017.10.034","article-title":"The antipsychotic drug brexpiprazole reverses phencyclidine-induced disruptions of thalamocortical networks","volume":"27","author":"van den Munkhof","year":"2017","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib315","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1001\/jamapsychiatry.2021.1422","article-title":"Functional connectivity in antipsychotic-treated and antipsychotic-naive patients with first-episode psychosis and low risk of self-harm or aggression: a secondary analysis of a randomized clinical trial","volume":"78","author":"Chopra","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib316","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1093\/schbul\/sbz087","article-title":"Effect of risperidone monotherapy on dynamic functional connectivity of insular subdivisions in treatment-naive, first-episode schizophrenia","volume":"46","author":"Duan","year":"2020","journal-title":"Schizophr. Bull."},{"issue":"2\u20133","key":"10.1016\/j.phrs.2022.106078_bib317","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.schres.2012.03.019","article-title":"Hippocampal novelty activations in schizophrenia: disease and medication effects","volume":"138","author":"Tamminga","year":"2012","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib318","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.nicl.2014.10.004","article-title":"Altered functional connectivity links in neuroleptic-na\u00efve and neuroleptic-treated patients with schizophrenia, and their relation to symptoms including volition","volume":"6","author":"Pu","year":"2014","journal-title":"NeuroImage Clin."},{"key":"10.1016\/j.phrs.2022.106078_bib319","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2147\/NDT.S123598","article-title":"Resting-state functional connectivity changes within the default mode network and the salience network after antipsychotic treatment in early-phase schizophrenia","volume":"13","author":"Wang","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib320","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.euroneuro.2016.11.002","article-title":"Olanzapine modulation of long- and short-range functional connectivity in the resting brain in a sample of patients with schizophrenia","volume":"27","author":"Guo","year":"2017","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib321","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2020.113338","article-title":"Effects of chronic pharmacological treatment on functional brain network connectivity in patients with schizophrenia","volume":"295","author":"Lin","year":"2021","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.phrs.2022.106078_bib322","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.schres.2018.07.045","article-title":"Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia","volume":"204","author":"Cadena","year":"2019","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib323","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41537-018-0051-y","article-title":"Evaluation of fronto-striatal networks during cognitive control in unmedicated patients with schizophrenia and the effect of antipsychotic medication","volume":"4","author":"Cadena","year":"2018","journal-title":"NPJ Schizophr."},{"issue":"3","key":"10.1016\/j.phrs.2022.106078_bib324","first-page":"448","article-title":"Systematic review of the influence of antipsychotics on the blood oxygenation level-dependent signal of functional magnetic resonance imaging","volume":"20","author":"R\u04e7der","year":"2013","journal-title":"Curr. Med. Chem."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib325","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-011-2214-7","article-title":"Functional magnetic resonance imaging of a parametric working memory task in schizophrenia: relationship with performance and effects of antipsychotic treatment","volume":"216","author":"Ettinger","year":"2011","journal-title":"Psychopharmacology"},{"issue":"17","key":"10.1016\/j.phrs.2022.106078_bib326","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1007\/s00213-015-3959-1","article-title":"Common and distinct neural effects of risperidone and olanzapine during procedural learning in schizophrenia: a randomised longitudinal fMRI study","volume":"232","author":"Kumari","year":"2015","journal-title":"Psychopharmacology"},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib327","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.euroneuro.2015.09.016","article-title":"Effects of haloperidol and aripiprazole on the human mesolimbic motivational system: a pharmacological fMRI study","volume":"25","author":"Bolstad","year":"2015","journal-title":"Eur. Neuropsychopharmacol.: J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib328","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3389\/fnhum.2015.00296","article-title":"No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol","volume":"9","author":"Bolstad","year":"2015","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.phrs.2022.106078_bib329","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.schres.2019.11.017","article-title":"Distinct striatum pathways connected to salience network predict symptoms improvement and resilient functioning in schizophrenia following risperidone monotherapy","volume":"215","author":"Han","year":"2020","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib330","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00213-011-2278-4","article-title":"The D2 antagonist sulpiride modulates the neural processing of both rewarding and aversive stimuli in healthy volunteers","volume":"217","author":"McCabe","year":"2011","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib331","doi-asserted-by":"crossref","first-page":"109","DOI":"10.31887\/DCNS.2016.18.1\/gjuckel","article-title":"Inhibition of the reward system by antipsychotic treatment","volume":"18","author":"Juckel","year":"2016","journal-title":"Dialog-. Clin. Neurosci."},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib332","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1503\/jpn.150234","article-title":"Dysfunctional insular connectivity during reward prediction in patients with first-episode psychosis","volume":"41","author":"Schmidt","year":"2016","journal-title":"J. Psychiatry Neurosci.: JPN"},{"issue":"8","key":"10.1016\/j.phrs.2022.106078_bib333","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00213-016-4234-9","article-title":"An investigation into aripiprazole's partial D\u2082 agonist effects within the dorsolateral prefrontal cortex during working memory in healthy volunteers","volume":"233","author":"Murphy","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib334","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neuroimage.2013.02.053","article-title":"Quetiapine modulates functional connectivity in brain aggression networks","volume":"75","author":"Klasen","year":"2013","journal-title":"NeuroImage"},{"key":"10.1016\/j.phrs.2022.106078_bib335","doi-asserted-by":"crossref","DOI":"10.1016\/j.pscychresns.2020.111085","article-title":"Effect of brexpiprazole on control of impulsivity in schizophrenia: a randomized functional magnetic resonance imaging study","volume":"301","author":"van Erp","year":"2020","journal-title":"Psychiatry Res. Neuroimaging"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib336","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/JCP.0000000000000600","article-title":"Quetiapine extended release open-label treatment associated changes in amygdala activation and connectivity in anxious depression: an fMRI study","volume":"36","author":"Altinay","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib337","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyv080","article-title":"Local and global resting state activity in the noradrenergic and dopaminergic pathway modulated by reboxetine and amisulpride in healthy subjects","volume":"19","author":"Metzger","year":"2015","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib338","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/npjschz.2016.14","article-title":"Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory","volume":"2","author":"Hadley","year":"2016","journal-title":"NPJ Schizophr."},{"key":"10.1016\/j.phrs.2022.106078_bib339","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.schres.2019.03.015","article-title":"Effect of second-generation antipsychotics on brain network topology in first-episode schizophrenia: a longitudinal rs-fMRI study","volume":"208","author":"Wang","year":"2019","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.phrs.2022.106078_bib340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3389\/fpsyt.2017.00014","article-title":"Risperidone effects on brain dynamic connectivity \u2013 a prospective resting-state fMRI study in schizophrenia","volume":"8","author":"Lottman","year":"2017","journal-title":"Front. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib341","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrn2774","article-title":"Abnormal neural oscillations and synchrony in schizophrenia","volume":"11","author":"Uhlhaas","year":"2010","journal-title":"Nat. Rev. Neurosci."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib342","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1139\/jpn.0903","article-title":"Neural synchrony in patients with a first episode of schizophrenia: tracking relations with grey matter and symptom profile","volume":"34","author":"Williams","year":"2009","journal-title":"J. Psychiatry Neurosci.: JPN"},{"issue":"12","key":"10.1016\/j.phrs.2022.106078_bib343","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/s41398-017-0002-9","article-title":"Cortical high gamma network oscillations and connectivity: a translational index for antipsychotics to normalize aberrant neurophysiological activity","volume":"7","author":"Ahnaou","year":"2017","journal-title":"Transl. Psychiatry"},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib344","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/j.1476-5381.2012.02107.x","article-title":"First and second generation antipsychotics influence hippocampal gamma oscillations by interactions with 5-HT3 and D3 receptors","volume":"167","author":"Schulz","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib345","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108572","article-title":"Effects of antipsychotic drugs and potassium channel modulators on spectral properties of local field potentials in mouse hippocampus and pre-frontal cortex","volume":"191","author":"Sun","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib346","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neuroscience.2018.04.035","article-title":"Beta and gamma oscillations in prefrontal cortex during NMDA hypofunction: an in vitro model of schizophrenia features","volume":"383","author":"Rebollo","year":"2018","journal-title":"Neuroscience"},{"issue":"11","key":"10.1016\/j.phrs.2022.106078_bib347","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1017\/S1461145714000959","article-title":"Chronic administration of antipsychotics attenuates ongoing and ketamine-induced increases in cortical \u03b3 oscillations","volume":"17","author":"Anderson","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"5","key":"10.1016\/j.phrs.2022.106078_bib348","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1017\/S1461145711000848","article-title":"Acute administration of typical and atypical antipsychotics reduces EEG \u03b3 power, but only the preclinical compound LY379268 reduces the ketamine-induced rise in \u03b3 power","volume":"15","author":"Jones","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"7","key":"10.1016\/j.phrs.2022.106078_bib349","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1111\/bph.14923","article-title":"The novel antipsychotic cariprazine stabilizes gamma oscillations in rat hippocampal slices","volume":"177","author":"Meier","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2022.106078_bib350","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2014.03.025","article-title":"Metabotropic glutamate receptors regulate cortical gamma hyperactivities elicited by ketamine in rats","volume":"567","author":"Hiyoshi","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2022.106078_bib351","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107704","article-title":"Antipsychotics: mechanisms underlying clinical response and side-effects and novel treatment approaches based on pathophysiology","volume":"172","author":"Kaar","year":"2020","journal-title":"Neuropharmacology"},{"issue":"702","key":"10.1016\/j.phrs.2022.106078_bib352","article-title":"Antipsychotic drug responsiveness and dopamine receptor signaling; old players and new prospects","volume":"9","author":"Rampino","year":"2019"},{"issue":"4","key":"10.1016\/j.phrs.2022.106078_bib353","doi-asserted-by":"crossref","first-page":"pyu046","DOI":"10.1093\/ijnp\/pyu046","article-title":"Agonist and antagonist effects of aripiprazole on D\u2082-like receptors controlling rat brain dopamine synthesis depend on the dopaminergic tone","volume":"18","author":"Ma","year":"2014","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib354","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s40263-015-0278-3","article-title":"Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism","volume":"29","author":"de Bartolomeis","year":"2015","journal-title":"CNS Drugs"},{"issue":"26","key":"10.1016\/j.phrs.2022.106078_bib355","doi-asserted-by":"crossref","first-page":"3739","DOI":"10.2174\/1381612821666150605112105","article-title":"5-HT6 receptor antagonists: potential efficacy for the treatment of cognitive impairment in schizophrenia","volume":"21","author":"de Bruin","year":"2015","journal-title":"Curr. Pharm. Des."},{"issue":"1","key":"10.1016\/j.phrs.2022.106078_bib356","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pharmthera.2009.06.001","article-title":"Antipsychotic drug actions on gene modulation and signaling mechanisms","volume":"124","author":"Molteni","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2022.106078_bib357","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","article-title":"Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study","volume":"164","author":"Mamo","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib358","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.pnpbp.2017.02.012","article-title":"Re-arrangements of gene transcripts at glutamatergic synapses after prolonged treatments with antipsychotics: a putative link with synaptic remodeling","volume":"76","author":"Buonaguro","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.phrs.2022.106078_bib359","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00213-012-2953-0","article-title":"The relationship between antipsychotic D2 occupancy and change in frontal metabolism and working memory: A Dual [(11)C]raclopride and [(18)\u2009F]FDG imaging study with aripiprazole","volume":"227","author":"Kim","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.phrs.2022.106078_bib360","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.psychres.2018.12.030","article-title":"F-18)Fluorodeoxyglucose positron emission tomography studies of the schizophrenia spectrum: the legacy of Monte S. Buchsbaum, M.D","volume":"271","author":"Hazlett","year":"2019","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.phrs.2022.106078_bib361","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.656459","article-title":"Metabolite alterations in adults with schizophrenia, first degree relatives, and healthy controls: a multi-region 7T MRS study","volume":"12","author":"Wijtenburg","year":"2021","journal-title":"Front. Psychiatry"},{"issue":"6","key":"10.1016\/j.phrs.2022.106078_bib362","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1001\/jamapsychiatry.2021.0380","article-title":"Association of age, antipsychotic medication, and symptom severity in schizophrenia with proton magnetic resonance spectroscopy brain glutamate level: a mega-analysis of individual participant-level data","volume":"78","author":"Merritt","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.phrs.2022.106078_bib363","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2018.06.021","article-title":"Neuroimaging markers of antipsychotic treatment response in schizophrenia: an overview of magnetic resonance imaging studies","volume":"131","author":"Tarcijonas","year":"2019","journal-title":"Neurobiol. Dis."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661822000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:30:37Z","timestamp":1760913037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661822000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":363,"alternative-id":["S1043661822000238"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106078","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Present and future antipsychotic drugs: A systematic review of the putative mechanisms of action for efficacy and a critical appraisal under a translational perspective","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2022.106078","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106078"}}